Sign up
Pharma Capital

Proteomics International Laboratories set to ship first commercial batch of its immunoassay kit

PromarkerD is the world's first commercial test for predicting the onset of diabetic kidney disease.
The new immunoassay kit can be used by pathology laboratories

Proteomics International Laboratories Ltd (ASX:PIQ) will ship the first commercial batch of its new PromarkerD immunoassay kit on November 20, 2018 following positive performance verification results.

This follows the production of key antibody reagents in Puerto Rico, and manufacture of the kit in California, both instigated in partnership with licence partner Omics Global Solutions.

Positive verification results on the PromarkerD immunoassay kit will be presented today at the 18th Annual Diabetes Technology Meeting in North Bethesda, US.

The PromarkerD kit will be used to target new commercialisation deals in Japan and India, opening the door to further commercialisation discussions around the world.

Proteomics’ PromarkerD mass spectrometry Laboratory Developed Test (LDT) has already been licensed in USA, Mexico and Spain.

The LDT permits fast adoption of a new test in advanced markets and is being used to build market demand prior to the wider release of the PromarkerD kit.

The world-first test for predicting the onset of diabetic kidney disease was recently licensed to PHDx (Austin, Texas) for launch in the US.

It is also due to launch in Mexico and Spain in the New Year.

Proteomics managing director Dr Richard Lipscombe said: “Diabetes and diabetes-associated diseases are a major global health problem that put an ever-increasing burden on the health sector.

“PromarkerD could save the US healthcare system up to US$100 billion per year in direct costs associated with treating end-stage kidney disease."

“We are delighted that the results of the PromarkerD Kit have been accepted for presentation at the 18th Annual Diabetes Technology Meeting.

“This shows the power of the Promarker TM technology platform and what Proteomics International is doing in the field of predictive testing for global diseases”.

Register here to be notified of future PIQ Company articles
View full PIQ profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.